The daily business briefing: December 29, 2016
Trump touts Sprint plan to add American jobs, U.S. stocks struggle after S&P 500's worst day since elections, and more

- 1. Trump touts Sprint plan to bring 5,000 jobs to U.S.
- 2. Stocks struggle after biggest drop in months
- 3. Obama creates two new national monuments in Utah and Nevada
- 4. Takata stock soars after report of settlement with Justice Department
- 5. Cempra shares plunge after FDA balks over new drug application

1. Trump touts Sprint plan to bring 5,000 jobs to U.S.
President-elect Donald Trump on Wednesday announced that Softbank Chief Executive Masayoshi Son had promised to move 5,000 jobs at Softbank's telecom Sprint from other countries to the U.S. Trump also noted that Sofbank-backed satellite startup OneWeb would create 3,000 jobs. Sprint clarified that the jobs were part of Softbank's previously announced plan to create jobs, and that only some of its new jobs would be moved from abroad, while the rest would be newly created positions. Trump's announcement came after the latest in a series of direct talks he has had with corporate CEOs on boosting U.S. employment.
2. Stocks struggle after biggest drop in months
U.S. stocks had their worst drop in two months on Wednesday after new housing data showed sales of previously owned homes falling in November to their lowest level in nearly a year. The Dow Jones Industrial Average fell by 111 points, or 0.6 percent, while the S&P 500 lost 19 points (0.8 percent), its biggest drop in two months, and the Nasdaq Composite dropped 49 points, or 0.9 percent. Boeing stock dropped by 0.9 percent after Delta Air Lines canceled a $4 billion order for 18 Dreamliner jets. The benchmark U.S. indexes edged still lower before the opening bell on Thursday.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. Obama creates two new national monuments in Utah and Nevada
President Obama on Wednesday designated two new national monuments in Utah and Nevada, protecting 1.65 million acres of federal land. Most of it, 1.35 million acres, surrounds the Bears Ears Buttes in southeastern Utah. The rest is northeast of Las Vegas around Nevada's Gold Butte. The moves were the latest in a series of actions Obama has made to protect public lands and waters from development as time runs out for him to seal his environmental legacy before leaving office in January. Native American tribes and others have been pushing to protect the areas for years, but some locals and Republican lawmakers have called Obama's efforts to protect parts of the West a federal land grab.
4. Takata stock soars after report of settlement with Justice Department
Takata Corp. shares surged by as much as 16 percent on Wednesday after The Wall Street Journal reported that the Japanese automotive supplier was nearing a settlement with the U.S. Department of Justice over its faulty airbags. Under the deal, Takata reportedly would plead guilty to misconduct and pay penalties as high as $1 billion. The settlement could be finalized as early as next month. Takata said it was not the source of the newspaper's report. Justice Department officials declined to comment.
The Wall Street Journal Bloomberg
5. Cempra shares plunge after FDA balks over new drug application
Shares of pharmaceutical company Cempra dropped by 28 percent in pre-market trading Thursday after the company said the U.S. Food and Drug Administration had rejected its antibiotic for community-acquired bacterial pneumonia. The FDA said it could approve new applications for the drug, solithromycin, until the company resolved manufacturing issues and provided more safety data. An independent panel narrowly recommended FDA approval of the drug in November, but FDA scientists in a staff review highlighted a potentially concerning rise in liver enzymes from the drug's use.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.
-
Music reviews: Bon Iver, Valerie June, and The Waterboys
Feature "Sable, Fable," "Owls, Omens, and Oracles," "Life, Death, and Dennis Hopper"
By The Week US
-
Are bonds worth investing in?
the explainer They can diversify your portfolio and tend to be a safer investment than stocks
By Becca Stanek, The Week US
-
Elon has his 'Legion.' How will Republicans encourage other Americans to have babies?
Today's Big Question The pronatalist movement finds itself in power
By Joel Mathis, The Week US
-
Why Russia removed the Taliban's terrorist designation
The Explainer Russia had designated the Taliban as a terrorist group over 20 years ago
By Justin Klawans, The Week US
-
Inside the Israel-Turkey geopolitical dance across Syria
THE EXPLAINER As Syria struggles in the wake of the Assad regime's collapse, its neighbors are carefully coordinating to avoid potential military confrontations
By Rafi Schwartz, The Week US
-
'Like a sound from hell': Serbia and sonic weapons
The Explainer Half a million people sign petition alleging Serbian police used an illegal 'sound cannon' to disrupt anti-government protests
By Abby Wilson
-
The arrest of the Philippines' former president leaves the country's drug war in disarray
In the Spotlight Rodrigo Duterte was arrested by the ICC earlier this month
By Justin Klawans, The Week US
-
Ukrainian election: who could replace Zelenskyy?
The Explainer Donald Trump's 'dictator' jibe raises pressure on Ukraine to the polls while the country is under martial law
By Sorcha Bradley, The Week UK
-
Why Serbian protesters set off smoke bombs in parliament
THE EXPLAINER Ongoing anti-corruption protests erupted into full view this week as Serbian protesters threw the country's legislature into chaos
By Rafi Schwartz, The Week US
-
Who is the Hat Man? 'Shadow people' and sleep paralysis
In Depth 'Sleep demons' have plagued our dreams throughout the centuries, but the explanation could be medical
By The Week Staff
-
Why Assad fell so fast
The Explainer The newly liberated Syria is in an incredibly precarious position, but it's too soon to succumb to defeatist gloom
By The Week UK